About Kihealth
A precision molecular intelligence company.
Kihealth builds the molecular infrastructure to predict, detect, monitor and intercept disease earlier — translating foundational science into a scalable, clinically validated precision medicine platform.
Who we are
Built to identify disease before it changes a life.
For decades, medicine has waited for disease to declare itself. Kihealth was founded on a different premise: that biological change can be detected years earlier, at a molecular level, when intervention still alters the outcome.
Predict & detect
Molecular signal years ahead of symptoms or clinical diagnosis.
Monitor
Sensitive longitudinal readouts of therapeutic response and progression.
Intercept
Actionable insight delivered into routine clinical decision-making.
Our origin
From Yale discovery to commercial platform.
The foundational technology behind Kihealth originated at Yale University, where pioneering work by Dr. Kevan Herold demonstrated that beta-cell injury could be detected using circulating biomarkers — revealing molecular signals long before symptoms, diagnosis, or irreversible damage.
That discovery created a rare commercial opportunity: to rethink how chronic disease, beginning with Type 1 and Type 2 diabetes, is identified. Kihealth was founded in 2023 to translate this science out of the academic setting and into diagnostics delivered reliably, affordably and at scale.
Today the company advances and commercializes that technology through its high-complexity molecular laboratory in St. Augustine, Florida, alongside leading physicians, academic institutions, health systems and industry partners.
Founded
2023
Headquarters
St. Augustine, FL
Why Kihealth exists
Healthcare must move from reaction to interception.
The economics and the outcomes of chronic disease are determined long before diagnosis. Kihealth is built for the transition already underway.
Healthcare past
Reactive
- 01Symptoms
- 02Diagnosis
- 03Treatment
Healthcare future
Preventive & precision
- 01Biological change
- 02Early detection
- 03Intervention
- 04Improved outcomes
Mission & vision
What drives us, and where we are going.
Our mission
Empowering clinicians with earlier, more actionable insight.
Deliver molecular insight that enables earlier disease detection, improves therapeutic decision-making, supports treatment monitoring and helps patients live healthier lives — moving healthcare from a reactive model to one centered on prevention, precision and earlier intervention.
Our vision
A healthcare system built around prevention, not consequence.
Molecular diagnostics as a routine part of clinical care — equipping physicians to identify disease earlier, personalize treatment, monitor response and improve outcomes across chronic disease, at population scale.
From scientific discovery to commercial platform
An academic breakthrough, engineered into a scalable company.
Each stage compounds the last — foundational science, protected intellectual property, validated assays, certified laboratory infrastructure, and a platform architected for multi-disease expansion.
- 01
Foundation
Yale University
Discovery of circulating beta-cell biomarkers in the laboratory of Dr. Kevan Herold establishes a new way to detect organ-specific injury before clinical presentation.
- 02
2023
Kihealth formed
Company established to translate foundational science into clinically accessible diagnostics, with exclusive rights and an expanding intellectual property position.
- 03
2023–2024
Laboratory infrastructure
CLIA- and COLA-certified high-complexity molecular laboratory established in St. Augustine, Florida, supporting assay development, validation and clinical reporting.
- 04
2024
Assay development & validation
Analytical validation completed as a laboratory-developed test, establishing sensitivity, specificity and reproducibility of the core molecular readout.
- 05
2024 & ongoing
Academic & clinical research
Multi-center research collaborations with leading academic and medical centers extend clinical evidence and support real-world utility.
- 06
2026
Ki Intelligence™
Proprietary AI and machine-learning layer integrating multi-omic signal, longitudinal clinical data and predictive modeling.
- 07
2026
Intercept IQ™
A scalable molecular diagnostics platform architected for disease interception across multiple indications.
- 08
2026
Beta Intercept™
First commercial-ready diagnostics on Intercept IQ™ — Beta Intercept™ T1D and T2D for earlier detection of beta-cell injury and metabolic dysfunction.
- 09
2026–2027
Multi-disease expansion
Platform extension beyond metabolic disease toward oncology and neurodegenerative indications, alongside pharmaceutical applications.
- 10
2027
Global opportunity
Commercial rollout across health systems nationally, with international market and partnership expansion.
Strategic foundation
Eight pillars underlying the platform.
01
Molecular Diagnostics
High-complexity assays built for clinical-grade sensitivity and reproducibility.
02
Multi-Omic Science
Integrated genomic, transcriptomic and proteomic signal across a single sample.
03
Artificial Intelligence
Ki Intelligence™ converts multi-omic and longitudinal data into predictive risk.
04
Clinical Validation
Multi-center studies and peer-reviewed evidence underwriting every claim.
05
Precision Medicine
The right intervention, for the right patient, at the right point in disease.
06
Disease Interception
Detection of biological change years before irreversible damage occurs.
07
Pharmaceutical Applications
Biomarkers that sharpen trial endpoints and monitor therapeutic response.
08
Scalable Multi-Disease Platform
One infrastructure, extensible across indications and geographies.
Closing
Kihealth is building the molecular intelligence infrastructure for the future of preventive medicine.